Three series of semi-synthetic derivatives of tylosin-related macrolides were evaluated for utility in veterinary medicine. 23-Modified derivatives of 5-0-mycaminosyltylonolide (OMT)possessed potent activity in vitro against species of Pasteurella and Mycoplasma. An experimental infection in chicks caused by Pasteurella multocida was utilized to evaluate efficacy; several of these derivatives of OMTeffectively treated the infection when given subcutaneously, but none were effective after oral administration in drinking water. Macrolides Tylosin is a valuable antibiotic in veterinary medicine.^The isolation of a large numberof biosynthetic intermediates and shunt metabolites (Scheme 1) from various biosynthetically-blocked mutant strains of Streptomyces fradiae1"0 prompted an extensive evaluation of their potential application in veterinary areas. In this paper, we report the results of our initial survey of activity against several important veterinary pathogens for several series of semisynthetic derivatives of tylosinrelated macrolides.
(Received for publication March 8, 1988 ) JULY 1988 Three series of semi-synthetic derivatives of tylosin-related macrolides were evaluated for utility in veterinary medicine. 23-Modified derivatives of 5-0-mycaminosyltylonolide (OMT)possessed potent activity in vitro against species of Pasteurella and Mycoplasma. An experimental infection in chicks caused by Pasteurella multocida was utilized to evaluate efficacy; several of these derivatives of OMTeffectively treated the infection when given subcutaneously, but none were effective after oral administration in drinking water. Macrolides retaining the 4'-0-mycarosyl moiety (tylosin, DMT) had relatively poor activity against Pasteurella in vitro. Certain 20-modified derivatives of desmycosin demonstrated good oral bioavailability in chicks and a lead compound with oral efficacy in the Pasteurella infection model was discovered.
Tylosin is a valuable antibiotic in veterinary medicine.^The isolation of a large numberof biosynthetic intermediates and shunt metabolites (Scheme 1) from various biosynthetically-blocked mutant strains of Streptomyces fradiae1"0 prompted an extensive evaluation of their potential application in veterinary areas. In this paper, we report the results of our initial survey of activity against several important veterinary pathogens for several series of semisynthetic derivatives of tylosinrelated macrolides.
Results and Discussion C-23 Derivatives of DMTand OMT:In Vitro Activity The synthesis of a large number of 23-0-acyl derivatives of 23-demycinosyltylosin (DMT)and 5-0-mycaminosyltylonolide (OMT) encompassing a wide variety of acyl substituents has been reported.5>6) These ester derivatives generally possessed excellent in vitro antimicrobial activity against Gram-positive bacteria and were often more potent than their respective parent compounds(DMT and OMT).Unfortunately, these derivatives were less efficacious against experimental infections in rodents and, in particular, exhibited no significant in vivo activity after oral administration.5) Similar conclusions were drawn from the evaluation of an extensive series of 23-modified derivatives of OMT involving substituents at C-23 other than esters, such as ethers, thioethers, halides and amines.7~9)
As was found for the ester derivatives, these C-23 non-ester derivatives treated experimental infections in rodents poorly after oral administration.70 Species of the genera Mycoplasmaand Pasteurella are often responsible for serious infections of the respiratory tract in animals raised for food.0 Representative 23-modified derivatives of OMT possessed excellent activity in vitro against selected species of Mycoplasmaand Pasteurella, with MICs DOMM  DOML  y^\\^o-CHO   I  OH  OH   DMT  OMT  OH  CHO  DMOT  DOMT  H  CHO  DOD MT  DOOMT  OH  CH3  DOD MOT  DODOMT  H  CH3 well within the therapeutically useful range ( Table 1 ). The activity of most derivatives was generally better than that of OMTitself; the exceptions were those compounds containing very polar (23-NH2, 17) or long lipophilic (23-0-octanoyl, 8) substituents, in accord with previous results against species of Staphylococci and Streptococci.5»7) An analogous evaluation of representative 23-modified derivatives of DMT revealed excellent activity against Mycoplasma species, but poorer activity against Pasteurella species ( Table 2) . The 23-modified non-ester derivatives (27~30) were prepared from DMTby SN2 displacement reactions on 23-0-(trifluoromethanesulfonyl)-DMT (see Experimental section). These in vitro results indicated that improvements in the activity of tylosin against Pasteurella species would most likely occur with those macrolides lacking the saccharide mycarose. This is consistent with other reports indicating an increase of in vitro activity against Gram-negative bacteria for the demycarosyl series of macrolides.3 * 5> 8) Abbreviations: See Table 1 and Scheme 1.
C-23 Derivatives of DMTand OMT: In Vivo Activity Initially, the evaluation of macrolides for efficacy against Pasteurella infections was performed in mice. OMT,given subcutaneously, successfully treated such infected mice (Table 3 ). This result was subsequently extended to the successful treatment of pneumonia caused by Pasteurella in both pigs and calves, in which OMTwas given by injection.100
However, attempts to treat infected mice by oral administration of OMTand its derivatives gave irreproducible results, probably due to the relatively poor and erratic oral absorption of this class of compoundsin rodents. The use of tylosin in poultry for the treatment of chronic respiratory disease due to Mycoplasma is well-known. As an alternative to testing in mice, an experimental Pasteurella infection in one-day-old chicks was established for Tables 1 and 2 . b Deaths within group of 10 treated chicks. c Compoundadministered in drinking water.
-: Not tested due to poor parenteral activity. Compound numbers: See Tables 1 and 2 . Compounds given by sc injection at 60 mg/kg (2 mg/chick).
evaluation of macrolide derivatives by both parenteral and oral administration. Measurable blood levels were obtained for tylosin after oral dosing at 50 and 100 mg/kg (see below), demonstrating its bioavailability by the oral route. In addition, our evaluation of derivatives against this model Pasteurella infection in chicks yielded results which were more consistent and reproducible than those obtained from the murine model. Consequently, all further evaluation of in vivo activity vs. Pasteurella was conducted using the experimental infection in chicks.
The efficacy of selected 23-modified derivatives of DMTand OMTagainst our model Pasteurella infection in chicks is recorded in Table 4 . OMTand several of its ester derivatives gave complete protection when administered subcutaneously at 30 mg/kg. However, most of the non-ester derivatives were muchless efficacious after parenteral dosing, suggesting that the ester derivatives might be hydrolyzed back to OMTin vivo. A more detailed pharmacokinetic and metabolic study would be necessary to answer this question. As anticipated from their reduced in vivo activity, the derivatives of DMTand tylosin were less effective in vivo, indicating that the demycarosyl series of macrolides were the more promising compounds against this Gram-negative bacterium. Unfortunately, there was little indication of efficacy after oral dosing with any of these compounds.
Representative derivatives of OMT and DMTwere also tested in vivo against an experimental infection in chicks caused by Mycoplasma gallisepticum (Table 5 ). However, none of the derivatives treated as well as tylosin when given by subcutaneous injection. The degree of treatment was improved if the derivatives were given four times rather than once, but in spite of excellent MICs, none of the derivatives appeared superior to tylosin in vivo.
C-20 Derivatives of Tylosin and Desmycosin : In Vitro Activity During the course of the evaluation described above, another series of macrolide derivatives was discovered which was orally efficacious against experimental infections in mice and yielded higher blood levels after oral administration to rodents. These derivatives were modified at the C-20 aldehyde group of tylosin and desmycosin by a wide variety of different functional groups.n) In vitro evaluation of these compoundsagainst veterinary pathogens indicated that many of the derivatives of desmycosin had only moderate activity against Pasteurella species (Table 6 ). However, a few derivatives (37, 43 and 46) showed somewhat lower MIC values than those obtained for the parent macrolide (desmycosin).
Analogous C-20 derivatives of tylosin were inactive against Pasteurella species, in accord with the previous conclusion that the 4'-0-mycarosyl series had poor in vitro activity against this Gramnegative bacterium. Most of the 20-modifled derivatives of tylosin and desmycosin showed relatively good in vitro activity against M. gallisepticum and Mycoplasmasynoviae but poor activity against Mycoplasma hyorhinis; in contrast, their parent macrolides (tylosin and desmycosin) had good activity against all three species. Unfortunately, no correlations could be established concerning in vitro activity between Gram-positive bacteria (Staphylococci and Streptococci), Pasteurella species and Mycoplasmaspecies. C-20 Derivatives of Tylosin and Desmycosin : In Vivo Activity Following oral administration of tylosin at either 100 or 50 mg/kg to chicks, measurable peripheral plasma levels were obtained, demonstrating better oral bioavailability of tylosin in chicks as compared to mice or rats.n) Furthermore, a substantial increase in plasma concentration and duration occurred with the 20-modified derivatives of tylosin and desmycosin as compared to the parent macrolides (Table 7) . This result extended our previous report of this effect in rodents for the series of aldehyde-modified derivatives.n) In contrast, neither OMTnor its 23-phenylacetyl derivative (3) gave measurable plasma levels in chicks following an oral dose of 100 mg/kg; their lack of measurable plasma levels after oral dosing is most likely responsible for their lack of oral efficacy in the chick protection test.
Although desmycosin, 20-dihydrodesmycosin (31) and lactenocin protected chicks against Pasteurella infections when administered subcutaneously at 30 mg/kg x 2, many 20-modified derivatives of desmycosin did not protect at this dose (Table 8) , despite comparable MICvalues against this bacterium. Other considerations such as pharmacokinetics, tissue distribution, the nature of the infection and the mechanismof antibacterial inhibition must be important factors which are not understood at this time. However, in contrast to the majority of derivatives tested, the heptamethyleneamino derivative (46) gave complete protection at subcutaneous doses of both 30 and 15 mg/kg x2. Even Table 6 . b Deaths within group of 10 treated chicks. c Compoundadministered in drinking water.
-: Not tested due to poor parenteral activity. 10/10 7/9 9/10 9/10 2/10 5/10 6/10 9/9 0/10 a Compoundnumbers: See Table 6 . b Given by gavage twice per day, 5 total doses, in a quantity equivalent to a daily consumption of 20 ml of drinking water.
more unexpectedly, this derivative (46) afforded protection against Pasteurella infection when administered to chicks in their drinking water at a dosage of 0.53 g/liter. Furthermore, both the parenteral and oral efficacy showed a good dose response. These favorable results represented the first positive lead in our search for a new, orally effective macrolide derivative with activity against both Pasteurella multocida and Pasteurella haemolytica. The extension of these results to the synthesis and identification of tilmicosin (EL-870)ir) as a therapeutic agent for treatment of pneumonia in swine and calves will be reported in forthcoming publications.13'1Ê valuation of representative 20-modified derivatives of desmycosin against an experimental infection due to M. gallisepticum in chicks also indicated efficacy after oral administration in this particular model (Table 9) . Again, the reductive animation derivative 46 appeared to give somewhat better efficacy than other 20-modified derivatives of desmycosin, even though all of the compounds had good in vitro activity against M. gallisepticum. In this experiment, 46 was comparable to tylosin, indicating that further evaluation and structure-activity studies within the series of reductive amination products of desmycosin were warranted.13 » 16)
Experimental
Materials and Methods XH NMRspectra were measured in CDC13solution on a Bruker WH-360or Jeol FX90ANMR
spectrometer; chemical shifts are given in ppm from internal TMS. Field desorption mass spectra (FD-MS)were obtained on a Varian-MAT731 spectrometer using carbon dendrite emitters. UV spectra were measured in 95%ethanol solution on a Cary 219 spectrometer. IR spectra were recorded in chloroform solution on a Nicolet MX-1FT-IR spectrometer. Optical rotations were measured on a Perkin-Elmer Model 241 polarimeter. MP's were taken on a Mel-temp apparatus and are uncorrected. TLC was performed using E. Merck plates of Silica gel 60 with a fluorescent indicator (F-254); visualization was effected by UVlight. Product purification was carried out by chromatography on silica gel, using either flash chromatography techniques1*0 (E. Merck grade 60 Silica gel) or a Waters Model 500 Prep LC system. Antibiotic susceptibility data were obtained by microtiter procedures. Determination of in vivo activity against Pasteurella infections was conducted in 1-day-old chicks, in which compounds were administered parenterally or orally after challenge of the chicks with P. multocida (0.1 ml of a 104-dilution of a 20-hour Tryptose broth culture of an avian P. multocida given subcutaneously). In these tests, unless indicated otherwise, all non-medicated infected chicks died within 24 hours of Pasteurella challenge. For parenteral administration, the compounds were administered by subcutaneous injection at the specified dosage, either 1 (if single injection) or 1 and 4 hours post-challenge of the chicks with P. multocida. Testing for oral efficacy was conducted by dissolution of the compounds in the chicks' drinking water, provided ad libitum. In vivo activity against Mycoplasmawas determined after infections were induced in chicks by injecting 0.2 ml of a broth culture of M. gallisepticum into the abdominal air sac of 2-to 3-day-old chicks. The compounds were administered by gavage five times at a dose equivalent to 0.13 g/liter (on the day of challenge once prior to and once following the challenge, two times on the next day and once on the third day). Twenty-one days post-infection, a blood sample was taken to measure antibodies to M. gallisepticum and the chicks were sacrificed. The presence or absence of air sac lesions was recorded. Peripheral plasma levels were determined by microbiological assay using Micrococcus luteus seeded in Difco Antibiotic Media No. 1. Zone sizes were measured with a Fisher Zone Reader and antibiotic concentrations were calculated from the standard curve for the appropriate compound.Concentrations represent an average value from 6 chicks per time period.
23-Azido-23-deoxy-DMT (28) A solution of DMT(15.0 g, 20.2 mmol) and^m-collidine (5.8 ml, 43.7 mmol) in dichloromethane (250 ml) was cooled to -78°C under argon and treated dropwise with trifluoromethanesulfonic anhydride (5.9 ml, 34.5 mmol) and then with lithium azide (2.975 g, 60.7 mmol). The cooling bath was removed and after 30 minutes, the reaction mixture was diluted with acetonitrile to bring the lithium azide into solution. After 2 hours, the reaction mixture was evaporated to dryness, and the residue was dissolved in dichloromethane. This solution was extracted with saturated sodium bicarbonate solution, dried (sodium sulfate), filtered and evaporated. The crude product was purified by silica gel chromatography, eluting with a linear gradient of dichloromethane (4 liters) and methanoldichloromethane (3 : 22, 4 
A solution of 23-azido-23-deoxy-DMT (7.98 g, 10.4 mmol), triphenylphosphine (2.86 g, 10.9 mmol) and water (0.25 ml, 13.9 mmol) in distilled THF (200 ml) was stirred at room temperature for 4 days.19) The reaction mixture was evaporated to give a glassy solid which was partitioned between ethyl acetate and 0.1 macetic acid solution. The aqueous layer was separated, washed with ethyl acetate and carefully poured into saturated sodium bicarbonate solution. The resulting mixture was extracted with dichloromethane, dried, filtered and evaporated to give 7.5 g (97.5 %) of 23-amino-23- N 3.78, calcd for C38H64N2O12: C 61.60, H 8.71, N 3.78. 23-(Phenylacetyl)amino-23 -deoxy-DMT (30) A solution of 23-amino-23-deoxy-DMT (1.48 g, 2.0 mmol) in 10% aqueous acetone (50 ml) was treated with iV-(phenylacetyl)oxysuccinimide (446 mg, 2.0 mmol) and stirred at room temperature for
